[Immunomodulatory therapy in severe pneumonia: a double-edged sword in determining clinical outcomes].

Severe pneumonia remains a major threat to human health, particularly in patients who progress to sepsis, with immune dysregulation playing a central role in its pathophysiological mechanism. Although immunomodulatory therapies have evolved alongside our improved understanding of immune imbalance, conflicting clinical evidence persists. For example, agents targeting similar pathways may produce divergent outcomes, while those with opposing mechanisms of action may yield comparable results. This heterogeneity likely stems from dynamic variations in the host's baseline status, pathogen type, disease stage, and therapeutic timing. Future breakthroughs will require a framework for precision immune profiling that integrates dynamic biomarker monitoring, metabolic modulation, and AI-assisted decision-making. The aim of such strategies is to achieve therapy that is tailored to the individual patient, optimized over time, and balances pathological suppression with host defense preservation. This will advance immunomodulatory therapies from empirical approaches to precision medicine paradigms.